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ABSTRACT
Nonobese diabetic recombination activating gene–null perforin-null (NOD-Rag1nullPrf1null) mice, which to-
tally lack mature T and B cells and natural killer cell cytotoxic function, survive longer and are easier to breed
than NOD-severe combined immunodeficiency (scid) or NOD-scid/2-microglobulin
null mice. We have tested
the use of NOD-Rag1nullPrf1null mice as recipients in a long-term xenograft assay for human hematopoietic
stem cells (HSCs) by adopting Yoder and colleagues’ method of conditioned newborn mice, with minor
modifications. Pregnant NOD-Rag1nullPrf1null dams were treated with busulfan 22.5 mg/kg. On the day of
delivery, the busulfan-exposed pups underwent transplantation with 4 to 5 million T cell–depleted human cord
blood mononuclear cells via the facial vein. At 2 months after transplantation, all 11 transplanted mice showed
human hematopoietic engraftment in the peripheral blood. At 6 months after transplantation, human cells
were detected in 5 mice, which showed higher than 0.9% human cell engraftment at 2 months. The mean
percentage of human CD45 cells in the bone marrow of engrafted mice was 43.9%  36.5% (range,
2.0%-79.9%). Next, we tested the usefulness of conditioned newborn NOD-Rag1nullPrf1null mice for applica-
tions to characterize the dye efflux capability and phenotypic features of human HSCs. Given that cord blood
HSCs have the ability to efflux rhodamine 123 (Rho), we attempted transplantations of sorted cells that
retained a low level (Rholow) or high level (Rhohigh) of Rho. Six-month engraftment was found only with the
Rholow cells, which contained high percentages of CD34CD38 cells and side population cells with Hoechst
33324 efflux activity. These observations suggest that Rholow cells are highly enriched for primitive hemato-
poietic cells. Accordingly, conditioned newborn NOD-Rag1nullPrf1null mice provide a desirable model for an
assay of long-term transplantable human HSCs.
© 2005 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Several transplantation models based on immune-
eﬁcient mice have been developed as assays for hu-
an hematopoietic stem cells (HSCs). In 1988, Mc-
une et al. [1] ﬁrst described the scid-hu model, in
hich long-term engraftment of human lymphomy-
loid cells was established by transplanting fetal hu- r
B&MTan tissues, such as liver, bone, thymus, and lymph
odes, into C.B-17-severe combined immunodeﬁ-
iency (scid) mice. C.B-17-scid mice are homozygous
or a mutation (Prkdcscid) in the catalytic subunit of a
NA-dependent protein kinase (Prkdc), which func-
ions in DNA double-strand break repair and V(D)J
ecombination in immunoglobulin and T-cell recep-
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4ors. Therefore, scid mice are radiosensitive and lack
erum antibody and functional T and B cells [1-3].
ubsequently, nonobese diabetic (NOD)-scid mice,
hich lack hemolytic complement and show reduced
acrophage function and natural killer (NK) cell ac-
ivity [4], have been widely used as recipients in the
enograft assay for human lymphocytes [5] and HSCs
rom human umbilical cord blood (CB) [6-8], bone
arrow (BM) [9,10], mobilized peripheral blood (PB)
11,12], and fetal liver [13,14]. One major problem
ith this strain of mice is the low level of engraftment
xcept when large numbers of cells are injected. This
s probably caused by the presence of residual NK cell
ytotoxic activity [15]. Furthermore, NOD-scid mice
ecome leaky and generate mature lymphocytes with
ge [4]. NOD-scid/2-microglobulin (B2m)null mice
ave been reported to have further reduced NK cell
ytotoxic activity and to support higher levels of hu-
an cell engraftment than NOD-scid mice [15]. We
reviously reported that the use of conditioned new-
orn NOD-scid/B2mnull mice allows measurement of
uman hematopoietic engraftment up to 4 months
fter transplantation [16,17]. Longer-term experimen-
ation with this strain of mice, however, is limited by
heir short life span, which is caused by the spontane-
us development of lymphomas [15,18]. In addition,
his strain of mice is highly radiosensitive and dif-
cult to breed. Another immune-incompetent
ouse model, NOD-recombination activating gene
Rag1)null mice, which are radiation resistant and to-
ally lack mature T and B cells because of a complete
nability to initiate V(D)J recombination, seem to pro-
ide longer-term human cell engraftment and are eas-
er to breed than NOD-scid mice [19]. Genetic cross-
ng of perforin (Prf1) gene–targeted mutation onto a
OD-Rag1null strain results in the absence of NK cell
ytotoxic function. In these mice, NK cells are not
apable of killing target cells because of the absence of
erforin, the major mediator of cytotoxic activity [20].
o test the use of NOD-Rag1nullPrf1null mice as re-
ipients in a long-term xenograft assay for human
SCs, we adopted Yoder and colleagues’ [21] method
f conditioning newborn mice, with minor modiﬁca-
ions. In this article, we describe an assay that allows
igh-level multilineage hematopoietic engraftment
or longer than 6 months after transplantation of hu-
an CB cells.
Recently, several studies have indicated that HSCs
n the BM of adult mice have the ability to efﬂux the
ye rhodamine 123 (Rho) [22-24]. This dye has an
fﬁnity for mitochondria, and its efﬂux is regulated by
he multidrug-resistant pump MDR1-encoded aden-
sine triphosphate–binding cassette transporter [25].
t has been reported that transplantable HSCs in adult
uman BM have a CD34Rholow phenotype [26]
r a CD34c-kitRholow phenotype [27]. Muench et
l. [28] also demonstrated an HSC phenotype in (
88ineageCD34Rholow human fetal liver cells. Re-
arding primitive hematopoietic cells in human CB,
iu and Verfaillie [29] reported that long-term cul-
ure-initiating cells were highly enriched in
D34CD33CD38c-kitRholow cells. Given that
he efﬂux activity is an important feature of HSCs in
B, we ﬁrst investigated Rho efﬂux capability of hu-
an CB transplantable HSCs by using transplantation
nto conditioned newborn NOD-Rag1nullPrf1null mice.
nly CB cells with a high Rho efﬂux capability were
apable of sustaining hematopoiesis for 6 months.
ATERIALS AND METHODS
ice
NOD/LtSz-Rag1nullPrf1null mice were generated
y Dr. Leonard D. Shultz (Jackson Laboratory, Bar
arbor, ME) [20] and have been bred and maintained
t the Veterans Affairs Medical Center of the Medical
niversity of South Carolina under deﬁned ﬂora in
entilated cages with irradiated food and ﬁltered
ater.
uman Umbilical CB Cells
Human CB cells were obtained from LifeSouth
ord Blood Bank of the University of Florida and
edical College of Virginia Hospitals. Mononuclear
ells (MNCs) were isolated from CB by density gra-
ient centrifugation at 350g for 30 minutes by using
ccupaque (Accurate Chemical and Scientiﬁc Corp.,
estbury, NY). For depletion of T cells, MNCs were
hen incubated with mouse antibodies against human
D3, CD4, and CD8 (Caltag Laboratories, Burlin-
ame, CA) for 30 minutes at 4°C. After washing, cells
ere incubated with sheep anti-mouse immunomag-
etic beads (Dynabeads M-450 coupled to sheep anti-
ouse immunoglobulin G; Dynal, Great Neck, NY)
or 30 minutes at 4°C, and unbound cells were har-
ested. In experiments testing Rho uptake, MNCs
ere incubated with mouse antibodies against human
D2, CD3, CD4, CD5, CD7, and CD8 (Caltag Lab-
ratories), and unbound cells were magnetically har-
ested by using Dynabeads.
ho Staining
Cells were suspended at 107/mL in Dulbecco
odiﬁed Eagle medium (DMEM) containing 2% fe-
al bovine serum and 1 mmol/L N-2-hydroxyeth-
lpiperazine-N-2-ethanesulfonic acid (DMEM) and
ncubated with Rho (Molecular Probes, Eugene, OR)
t 0.1 g/mL for 30 minutes at 37°C, as previously
escribed [30]. For inhibitor experiments, reserpine
Sigma, St. Louis, MO) was added to cells at a ﬁnal
oncentration of 5 mol/L. The cells were washed
nce with warm (37°C) Hanks balanced salt solution
HBSS) containing 2% fetal bovine serum and 1
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Bmol/L N-2-hydroxyethylpiperazine-N-2-ethanesul-
onic acid (HBSS), washed again with ice-cold
BSS containing 1 g/mL propidium iodide (PI),
nd resuspended in ice-cold HBSS. The Rho-labeled
ells were stained with allophycocyanin–conjugated
nti-CD38 (Becton Dickinson, San Jose, CA) or
D133 (Miltenyi Biotec, Auburn, CA) and a panel of
hycoerythrin-conjugated antibodies against CD2,
D3, CD4, CD5, CD7, CD8, CD11b, CD16, CD19,
r CD34 (Becton Dickinson) on ice for 30 minutes
nd were analyzed with a FACSCalibur (Becton Dick-
nson). Rholow and Rhohigh populations were sorted
ith a FACSVantage (Becton Dickinson).
ide Population Cell Analysis of Rho-Labeled Cells
The Rho-labeled cells were resuspended at
06/mL in DMEM and incubated with Hoechst
3342 (Sigma) at 5 g/mL for 60 minutes at 37°C, as
reviously described [31]. In some experiments, reser-
ine (Sigma) was added to the incubation media at a
nal concentration of 5 mol/L. The cells were
ashed twice with ice-cold HBSS containing PI 1
g/mL, resuspended in ice-cold HBSS, and then
nalyzed with a FACSVantage.
ransplantation
Busulfan (Sigma) was dissolved in dimethyl sulfox-
de at the concentration of 15 mg/mL, diluted 1:5 with
BSS, and then administered subcutaneously at a
ose of 22.5 mg/kg to pregnant NOD-Rag1nullPrf1null
ams at postcoital days 17.5 and 18.5. On the day of
elivery, newborn mice underwent transplantation via
njection through the facial vein with CB cells by
sing 29-gauge needles (Becton Dickinson, Franklin
ake, NJ).
PB cells were collected from recipients by retro-
rbital bleeding at various times after transplantation.
M cells were ﬂushed from femurs and tibias of re-
ipients by using 25-gauge needles, and single-cell
uspensions were prepared by repeated passage
hrough a 25-gauge needle. The samples were mixed
ith anti-CD16/32 (Becton Dickinson) to block non-
peciﬁc binding and were incubated with ﬂuorescein
sothiocyanate–conjugated anti-human CD45 and
hycoerythrin-conjugated anti-human CD34, CD33,
D19, and CD3 (Becton Dickinson) on ice for 30
inutes. PB erythrocytes were lysed in PharM Lyse
olution (Becton Dickinson). The samples were resus-
ended in phosphate-buffered saline with PI 1 g/mL
nd analyzed with a FACSCalibur.
ESULTS
ong-term Engraftment by T Cell–Depleted
ononuclear CB Cells
The use of NOD-Rag1nullPrf1null mice in an assay
or human HSCs was tested with Yoder and associ- c
B&MTtes’ method [21] of conditioning newborn mice, with
inor modiﬁcations. First, we tested various doses of
usulfan injected at varying times of gestation be-
ween 17 and 19 days after coitus. Subcutaneous in-
ection of 22.5 mg/kg to pregnant NOD-
ag1nullPrf1null dams at postcoital days 17.5 and 18.5
roved to be the optimal conditioning method (data
ot shown). To prevent preferential T-cell engraft-
ent, which tends to mask multilineage engraftment
16], CD3, CD4, and CD8 T cells were depleted
rom the CB MNCs. T cell–depleted MNCs con-
ained 2.5% CD34 cells (median; range, 1.1%-5.5%;
 4). We injected 4  106 to 5  106 T cell–
epleted MNCs into conditioned newborn NOD-
ag1nullPrf1null mice and followed up the engraftment
f human cells in PB every 2 months (Figure 1A). At
months after transplantation, all (11/11) trans-
lanted mice showed human hematopoietic engraft-
ent in the PB. At 6 months after transplantation,
owever, human cells were detected in the PB of only
mice, which showed higher than 0.9% human cell
ngraftment at 2 months. The levels of human
D45 cells were 6.3%, 5.8%, 4.1%, 1.3%, and 0.3%
Figure 1A). In the BM of these 5 mice, the levels of
uman CD45 cells were 69.8%, 79.9%, 60.5%,
.4%, and 2.0%, respectively (Figure 1B). Multilin-
age engraftment, including varying levels of
D45CD33, CD45CD19, and CD45CD34
ells, was conﬁrmed by phenotypic analysis (Figure
C-F). Only very low levels of CD45CD3 cells
ere detected (data not shown).
nrichment of Putative HSCs in CB
Studies of murine models demonstrated that
SCs have dye efﬂux capability [22-24]; this indicates
hat human HSCs may reside in the Rholow cell frac-
ion. We also wished to enrich human long-term en-
rafting cells by sorting with antibodies prepared
gainst cell-surface markers. Analyses of surface anti-
en expression by CB MNCs are presented in Table
. The markers for lymphoid cells, including CD2,
D3, CD4, CD5, CD7, and CD8, were detected in
igh proportions of Rholow cells, whereas those for
ature myeloid and B cells, such as CD11b, CD16,
nd CD19, were detected generally in lower percent-
ges of Rholow cells. Percentages of both CD34 cells
nd CD133 cells were higher in T cell–depleted
CD2CD3CD4CD5CD7CD8) Rholow cells
han in Rholow cells (Table 1). In addition, 52% of the
cell–depleted Rholow cells were CD34CD133
median; range, 16%-57%; n  3). Together these
bservations indicate signiﬁcant enrichment of long-
erm–engrafting primitive hematopoietic cells in T
ell–depleted Rholow cells.
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4ong-term Human Engraftment by T
ell–Depleted Rholow Cells
We then tested the dye efﬂux capability of human
B long-term–engrafting cells by using the condi-
ioned newborn NOD-Rag1nullPrf1null mice. We in-
ected 3  104 to 4  104 T cell–depleted
CD2CD3CD4CD5CD7CD8) Rholow or
.1  105 to 1.9  105 T cell–depleted Rhohigh cells
nto 5 newborn mice each. This reﬂects the ratio of
holow to Rhohigh cells presented in Figure 2A. Al-
igure 1. Six months of engraftment in mice transplanted with T
PB) of individual mice 2, 4, and 6 months after transplantation of 4
ells in the bone marrow (BM) of the individual mice showing huma
uorescence-activated cell-sorting analysis showing human multil
mmunoglobulin.
able 1. Analysis of Cell-Surface Markers on Rholow and T
ell–Depleted Rholow MNCs
Phenotype Rholow
CD2CD3CD4CD5
CD7CD8Rholow
D2 83.5% (66.7%–87.8%) ND
D3 71.4% (34.4%–80.2%) ND
D4 45.3% (31.6%–65.3%) ND
D5 84.8% (44.4%–83.7%) ND
D7 89.6% (85.2%–92.7%) ND
D8 22.5% (11.1%–36.7%) ND
D11b 15.6% (4.5%–41.0%) 3.5% (1.6%–6.3%)
D16 7.4% (4.6%–29.0%) 0.1% (0.0%–1.0%)*
D19 6.4% (0.31%–13.4%) 16.7% (4.7%–56.1%)
D34 3.9% (0.50%–5.2%) 80.8% (26.2%–87.9%)*
D133 3.9% (0.65%–4.2%) 53.0% (17.4%–69.2%)*
alues represent the median and range of the expression of various
surface antigens on Rholow and T cell–depleted Rholow cells
(n  3 to 5).
D indicates not done.
The difference between groups is signiﬁcant at P  .05 by thepMann-Whitney test.
90hough 2 mice that received Rholow cells died within 6
onths of transplantation, 8 mice survived 6 months
fter transplantation. Six-month engraftment was
ound only with the Rholow cells (Figure 2B). Varying
ultilineage engraftment was conﬁrmed in all en-
rafted mice by ﬂow cytometry. The percentage of
D45CD34, CD45CD33, and CD45CD19
ells ranged from 0.1% to 4.9%, 0.1% to 5.0%, and
.1% to 29%, respectively. An analysis of a represen-
ative recipient mouse is shown in Figure 2C-F. These
esults clearly indicate that long-term–engrafting cells
n human CB are Rholow.
Other hallmarks for primitiveness of hematopoi-
tic cells are a CD34CD38 phenotype [6] and side
opulation (SP) cells deﬁned by Hoechst 33342 ef-
ux [31]. T cell–depleted CB cells were stained with
ho in conjunction with either Hoechst 33342 or
ntibodies against CD34 and CD38. As presented in
igure 3, T cell–depleted Rholow cells contained
0% CD34CD38 cells and 15% SP cells, whereas
hohigh cells contained a very low percentage of
D34CD38 cells and fewer SP cells than MNCs.
hese observations are consistent with the engraft-
ent data presented previously and suggest that T
ell–depleted Rholow cells are highly enriched for
rimitive hematopoietic cells.
ISCUSSION
HSCs possess a self-renewal capability and can
pleted MNCs. A, Kinetics of engraftment in the peripheral blood
to 5  106 T cell–depleted MNCs. B, Percentage of donor CD45
n PB at 6 months after transplantation in (A). C-F, A representative
engraftment in the BM by T cell–depleted MNCs. Ig indicatescell–de
 106
n cells i
ineageroduce blood cells indeﬁnitely, whereas hematopoi-
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Btic progenitors are thought to be capable of blood
ell production only for limited durations. Therefore,
ongevity of engraftment may be the most essential
haracteristic of HSCs and may distinguish HSCs
rom progenitors. Most of the reports based on NOD-
cid or NOD-scid/B2mnull mice limit the observations
p to 2 months after transplantation, partly because of
he spontaneous development of thymic lymphomas
n the recipient mice [6,7,10,18,32]. Some investiga-
ors, however, have presented observations of engraft-
ent up to 5 months after transplantation by using
OD-scid/interleukin 2 receptor null (c
null) mice
33,34]. In our laboratory, we developed a method for
njecting human CB cells into conditioned newborn
ice, thereby acquiring an additional 2 months of
ngraftment before the mice reach adulthood. The
odel we described here, based on conditioned new-
orn NOD-Rag1nullPrf1null mice, allows engraftment
or longer than 6 months after transplantation. This,
oupled with relative ease of breeding, may make this
odel a desirable candidate for an assay of human
SCs.
Sensitivity, deﬁned as engraftment levels relative
o graft size, is another important gauge of a stem cell
ssay. The number of CB cells that we transplanted
er conditioned newborn NOD-Rag1nullPrf1null
ouse is half to one eighth of a usual CB sample, yet
igh-level human cell engraftment was sustained for 6
onths after transplantation. Dao et al. [35,36] re-
orted human engraftment 8 to 12 months after trans-
igure 2. Engraftment by T cell–depleted Rholow, but not Rhohigh
hohigh cell populations. The R1 gate was set on the live gate wind
he solid line indicates staining with Rho. The dotted line indicates
ells in the BM of individual mice transplanted with 3  104 to 4
ifference between the 2 groups was signiﬁcant at P .05 by the Ma
nalysis of human multilineage engraftment by Rholow cells at 6 mlantation of CD34CD38 cells into 6- to 8-week- o
B&MTld beige/nude/xid mice; however, the levels of
ngraftment were low. Recently, Traggiai et al. [37]
eported human cell engraftment 6 months after
ransplantation with CB CD34 cells into newborn
ALB/c-Rag2null/c
null mice, which lack B, T, and NK
ells, and Rozemuller et al. [38] reported enhanced
ngraftment at 4 months after transplantation in mac-
ophage-depleted Rag2null/c
null mice. However, the
ngraftment levels and graft sizes in these models were
ow.
The percentages of human CD45CD3 cells
ere very low in the BM, spleen, and thymus of the
ngrafted NOD-Rag1nullPrf1null mice, and this was in
ontrast to the high levels of human T-cell engraft-
ent seen in NOD-scid/c
null mice [33,34] and
ag2null/c
null mice [37]. This, however, may not sim-
ly be the result of strain differences in the recipient
ice. The recipient mice we used in these studies
ere conditioned newborn mice, whereas Ito et al.
33] and Hiramatsu et al. [34] used irradiated adult
ice. The methods used for stem cell enrichment and
-cell depletion are also different. We previously
oted that, when T cell–depleted CB MNCs were
ransplanted into conditioned newborn NOD-scid/
2mnull mice via intrahepatic or intraperitoneal routes,
referential T-cell engraftment masked myeloid and
-cell engraftment in some recipients [16]. By trans-
lanting CB cells via facial veins of the conditioned
ewborn NOD-scid/B2mnull mice, we achieved signif-
cant reductions in T-cell engraftment [16]. This
n CB cells. A, Sorting regions used for preparation of Rholow and
the forward scatter (FSC)/propidium iodide (PI) proﬁle of MNCs.
l staining with Rho and reserpine. B, Percentage of human CD45
Rholow or 1.1  105 to 1.9  105 Rhohigh cells at 6 months. The
itney test. C-F, A representative ﬂuorescence-activated cell-sorting
fter transplantation., huma
ow in
contro
 104
nn-Whbservation indicated that the route of cell adminis-
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4ration can cause variations in human T-cell engraft-
ent. Therefore, the differences in human T-cell
ngraftment seem to reﬂect multiple technical differ-
nces in these xenograft assays.
Studies using mouse models indicate that HSCs
ave dye efﬂux capability [22,24,31]. We investi-
ated the dye efﬂux capability of human CB long-
igure 3. Analyses of T cell–depleted Rholow and Rhohigh cells f
epresentative CD34/CD38 proﬁles of Rholow (A) and Rhohigh (B)
ogether, as well as SP cell analysis of CB MNCs without (E) anderm–engrafting cells by using our new model. The c
92esults clearly demonstrated that Rholow cells, but
ot Rhohigh cells, are able to engraft for 6 months
fter transplantation, thus indicating that human
ong-term–engrafting cells also possess dye efﬂux
apability. These results are also consistent with the
arlier studies in cell culture, which documented
hat most human CB long-term culture–initiating
ace marker expression and dye (Hoechst 33342) efﬂux capability.
nd SP cell analyses of Rholow (C) and Rhohigh (D) cells are shown
) reserpine.or surf
cells aells are in the RholowCD34CD33CD38 cells
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B29]. Our earlier studies of human CB cells that
sed conditioned newborn NOD-scid/B2mnull mice
uggested that the surface phenotype of human CB
SCs is CD34CD38 [17]. T cell–depleted
D34CD38Rholow cells seem to offer the best-
nriched population of HSCs in human CB.
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